228 related articles for article (PubMed ID: 12358935)
41. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
42. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
43. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
Conti RM; Padula WV; Larson RA
Ann Hematol; 2015 Apr; 94 Suppl 2(0 2):S249-57. PubMed ID: 25814091
[TBL] [Abstract][Full Text] [Related]
44. With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
Tuma RS
J Natl Cancer Inst; 2007 Feb; 99(3):192-4. PubMed ID: 17284712
[No Abstract] [Full Text] [Related]
45. Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.
Peggs K; Mackinnon S
N Engl J Med; 2003 Mar; 348(11):1048-50. PubMed ID: 12637616
[No Abstract] [Full Text] [Related]
46. [Induction of hospital indebtedness due to medicine purchases under monopoly conditions: the case of imatinib mesylate].
Scopel CT; Chaves GC
Cad Saude Publica; 2015 Mar; 31(3):575-85. PubMed ID: 25859724
[TBL] [Abstract][Full Text] [Related]
47. Chronic myelogenous leukemia: the news you have and haven't heard.
Kalaycio ME
Cleve Clin J Med; 2001 Nov; 68(11):913, 917, 920-1, 925-6. PubMed ID: 11718431
[TBL] [Abstract][Full Text] [Related]
48. After 30 years of laboratory work, a quick approval for STI571.
Arnold K
J Natl Cancer Inst; 2001 Jul; 93(13):972. PubMed ID: 11438558
[No Abstract] [Full Text] [Related]
49. Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia.
Xiao Y; Hu HH; Wang HX; Zhu XJ; Zou P; Chen ZC; Zhong ZD; Li WM; You Y
Acta Pharmacol Sin; 2012 Jul; 33(7):979-80. PubMed ID: 22684027
[No Abstract] [Full Text] [Related]
50. Imatinib mesylate for chronic myeloid leukemia: what do we really know?
Husereau D
Issues Emerg Health Technol; 2002 Dec; (42):1-4. PubMed ID: 12492100
[TBL] [Abstract][Full Text] [Related]
51. a suitable case for treatment. The National Institute for Clinical Excellence's change of heart over cancer drug Glivec has been applauded by clinicians--and patients.
Siddall R
Health Serv J; 2002 Aug; 112(5819):10. PubMed ID: 12356018
[No Abstract] [Full Text] [Related]
52. Not so NICE for CML.
Goldman J; Apperley J; Clark R; Green T; Holyoake T; O'Brien S; Shepherd P
Lancet; 2002 Jun; 359(9322):2036. PubMed ID: 12076575
[No Abstract] [Full Text] [Related]
53. New directions in the treatment of patients with chronic myeloid leukemia: introduction.
Baccarani M
Semin Hematol; 2009 Apr; 46(2 Suppl 3):S1-4. PubMed ID: 19621542
[No Abstract] [Full Text] [Related]
54. Chronic myeloid leukemia. Introduction.
Frame D
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S2-3. PubMed ID: 18056928
[No Abstract] [Full Text] [Related]
55. Chronic myeloid leukemia. Sceptical scientists.
Druker BJ
Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
[No Abstract] [Full Text] [Related]
56. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Zackova D; Klamova H; Muzik J; Cmunt E; Racil Z; Machova Polakova K; Dvorakova D; Jurcek T; Razga F; Cetkovsky P; Dusek L; Mayer J
Leuk Lymphoma; 2013 Oct; 54(10):2310-3. PubMed ID: 23373966
[No Abstract] [Full Text] [Related]
57. Pregnancy in patients with chronic myeloid leukemia treated with imatinib.
Yilmaz M; Demirhan O; Kuçukosmanoglu E; Pehlivan M; Okan V; Balat O; Pehlivan S
Leuk Lymphoma; 2007 Dec; 48(12):2454-6. PubMed ID: 18067024
[No Abstract] [Full Text] [Related]
58. From the Food and Drug Administration.
Schwetz BA
JAMA; 2001 Jul; 286(1):35. PubMed ID: 11434814
[No Abstract] [Full Text] [Related]
59. Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?
Yeung DT; White DL
Leuk Lymphoma; 2011 Feb; 52(2):165-7. PubMed ID: 21171867
[No Abstract] [Full Text] [Related]
60. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
